1
|
Bobillo S, Crespo M, Escudero L, Mayor R, Raheja P, Abrisqueta P, Palacio-Garcia C, Montoro J, Jimenez I, Nieto J, Carabia J, Martinez-Ricarte F, Castellvi J, Puigdefabregas L, Bosch F, Seoane J. ANALYSIS OF CIRCULATING TUMOR DNA (ctDNA) IN CEREBROSPINAL FLUID DETECTS THE PRESENCE OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN B-CELL LYMPHOMAS. Hematol Oncol 2019. [DOI: 10.1002/hon.3_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- S. Bobillo
- Laboratory of Experimental Hematology; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital; Barcelona Spain
| | - M. Crespo
- Laboratory of Experimental Hematology; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital; Barcelona Spain
| | - L. Escudero
- Gene Expression and Cancer Group; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital (HUVH); Barcelona Spain
| | - R. Mayor
- Gene Expression and Cancer Group; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital (HUVH); Barcelona Spain
| | - P. Raheja
- Laboratory of Experimental Hematology; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital; Barcelona Spain
| | - P. Abrisqueta
- Laboratory of Experimental Hematology; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital; Barcelona Spain
| | - C. Palacio-Garcia
- Laboratory of Experimental Hematology; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital; Barcelona Spain
| | - J. Montoro
- Laboratory of Experimental Hematology; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital; Barcelona Spain
| | - I. Jimenez
- Laboratory of Experimental Hematology; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital; Barcelona Spain
| | - J.C. Nieto
- Laboratory of Experimental Hematology; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital; Barcelona Spain
| | - J. Carabia
- Laboratory of Experimental Hematology; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital; Barcelona Spain
| | - F. Martinez-Ricarte
- Department of Neurosurgery; Vall d'Hebron University Hospital (HUVH); Barcelona Spain
| | - J. Castellvi
- Department of Pathology; Vall d'Hebron University Hospital; Barcelona Spain
| | - L. Puigdefabregas
- Laboratory of Experimental Hematology; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital; Barcelona Spain
| | - F. Bosch
- Laboratory of Experimental Hematology; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital; Barcelona Spain
| | - J. Seoane
- Gene Expression and Cancer Group; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital (HUVH); Barcelona Spain
| |
Collapse
|
2
|
Benítez Montañez J, Vieito Villar M, Hierro C, Gonzalez Rodriguez M, Matos I, Braña Garcia I, Suarez Rodriguez C, Martinez Saez E, Perez-Gago M, Morales-Barrera R, Ortiz C, Suarez C, Maldonado X, Martinez-Ricarte F, Auger C, Azaro A, Dienstmann R, Carles J, Garralda E. Impact of a molecular prescreening program (MPP) in the management of patients with non-glioblastoma brain tumors. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy273.364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
3
|
Dietrich P, Wick W, Hilf N, Frenzel K, Gouttefangeas C, Platten M, thor Straten P, Lassen U, Rodon J, Bukur V, Admon A, van der Burg SH, von Deimling A, Kroep JR, Martinez-Ricarte F, Okada H, Ottensmeier CH, Ponsati B, Poulsen HS, Stevanovic S, Tabatabai G, Rammensee H, Sahin U, Singh-Jasuja H. OS2.2 Highly personalized peptide vaccination for patients with newly diagnosed glioblastoma: the GAPVAC trial. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | - W Wick
- University of Heidelberg, Heidelberg, Germany
| | - N Hilf
- Immatics biotechnologies GmbH, Geneva, Germany
| | | | | | - M Platten
- University of Heidelberg, Campus Mannheim, Mannheim, Germany
| | | | - U Lassen
- Ringhospitalet Copenhagen, Copenhagen, Denmark
| | - J Rodon
- Vall d`Hebron, Barcelona, Spain
| | | | | | | | | | - J R Kroep
- University of Leiden University, Leiden, Belgium
| | | | - H Okada
- University of San Francisco, San Francisco, CA, United States
| | | | | | - H S Poulsen
- University of Copenhagen, Copenhagen, Denmark
| | | | | | | | | | | | | |
Collapse
|
4
|
Toledo M, Molins A, Quintana M, Santamarina E, Martinez-Ricarte F, Martínez-Saez E, Salas-Puig J. Outcome of cancer-related seizures in patients treated with lacosamide. Acta Neurol Scand 2018; 137:67-75. [PMID: 28832891 DOI: 10.1111/ane.12809] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/24/2017] [Indexed: 12/20/2022]
Abstract
OBJECTIVES Lacosamide is an antiepileptic drug (AED), which has proven to be effective to control seizures, including acute conditions such as status epilepticus. The aim of this study is to describe the clinical experience with lacosamide in neuro-oncological patients. MATERIALS AND METHODS Multicenter retrospective study in patients with cancer-related seizures, who received lacosamide as an add-on therapy. RESULTS Forty-eight patients with benign and malignant tumors, including primary brain tumors, lymphomas, systemic cancer with central nervous system involvement, or paraneoplastic encephalitis, were included. Lacosamide was effective in the control of chronic seizures in patients with either benign or malignant tumors. The success rate was greater in malignant tumors, and drug-resistant epilepsies were more likely associated with benign tumors. Adverse events occurred in nearly 70% of patients, particularly in acute conditions and associated with the concomitant use of radio-/chemotherapy. Lacosamide-related adverse events were more likely somnolence and dizziness, which usually resolved after dose adjustment. After starting lacosamide, nearly half of the patients discontinued one of the baseline AEDs and decreased or discontinued dexamethasone. Fifteen patients with status epilepticus were treated with intravenous lacosamide, and 73% of them had their condition resolved without serious drug-related adverse events. CONCLUSION Lacosamide is an AED to consider in cases of cancer-related seizures. Lacosamide pharmacodynamics and pharmacokinetics allow the achievement of responder rates over 50% with no serious adverse effects, amelioration of side effects from other AEDs or radio-/chemotherapy, and no significant drug interactions. Furthermore, the intravenous formulation shows clear benefits in acute conditions such as status epilepticus.
Collapse
Affiliation(s)
- M. Toledo
- Epilepsy Unit; Neurologý Department; Hospital Universitario Vall d′Hebron; Barcelona Spain
| | - A. Molins
- Epilepsy Unit; Neurology Department; Hospital Universitari Vall d′Hebron; Girona Spain
| | - M. Quintana
- Epilepsy Unit; Neurologý Department; Hospital Universitario Vall d′Hebron; Barcelona Spain
| | - E. Santamarina
- Epilepsy Unit; Neurologý Department; Hospital Universitario Vall d′Hebron; Barcelona Spain
| | - F. Martinez-Ricarte
- Neurosurgery Department; Hospital Universitario Vall d′Hebron; Barcelona Spain
| | - E. Martínez-Saez
- Neuropathology Department; Hospital Universitario Vall d′Hebron; Barcelona Spain
| | - J. Salas-Puig
- Epilepsy Unit; Neurologý Department; Hospital Universitario Vall d′Hebron; Barcelona Spain
| |
Collapse
|
5
|
Martinez-Ricarte F, Martinez-Saez E, Cicuendez M, Cordero E, Auger C, Toledo M, Radoi A, Sahuquillo J. [Atypical ganglioglioma with BRAF V600E mutation: a case report and review of the literature]. Rev Neurol 2016; 62:455-459. [PMID: 27149188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
INTRODUCTION Gangliogliomas are rare tumours that affect young patients, appear predominantly in the temporal lobe and usually begin with epileptic seizures. Histologically they have a grade I of malignancy, with an anaplastic form that is catalogued as grade III in the 2007 WHO classification. Yet, there are tumours that do not meet the criteria of either grade and which offer clear prognostic differences with respect to those of grade I. These tumours would be atypical gangliogliomas (grade II), which are not considered in this classification. From the molecular point of view, the best known alteration in gangliogliomas is the BRAF V600E mutation, which worsens the prognosis of the lesion. The possible use of treatments targeted towards this mutated protein is especially relevant in this disorder. CASE REPORT A 21-year-old male, who had undergone surgery due to a ganglioglioma on two occasions. The neuro-pathological examination revealed histological features consistent with an intermediate grade of malignancy (grade II), with positive BRAF mutation. CONCLUSIONS The case presented here, together with those previously reported in the literature, reopens the debate on the definition of gangliogliomas in the 2007 WHO classification, and lends support to the fact that the next classification should again include atypical gangliogliomas (grade II), together with possible genetic mutations and molecular disorders.
Collapse
Affiliation(s)
| | | | - M Cicuendez
- Hospitals Vall d'Hebron, 08035 Barcelona, Espana
| | - E Cordero
- Hospitals Vall d'Hebron, 08035 Barcelona, Espana
| | - C Auger
- Hospitals Vall d'Hebron, 08035 Barcelona, Espana
| | - M Toledo
- Hospitals Vall d'Hebron, 08035 Barcelona, Espana
| | - A Radoi
- Hospitals Vall d'Hebron, 08035 Barcelona, Espana
| | - J Sahuquillo
- Hospitals Vall d'Hebron, 08035 Barcelona, Espana
| |
Collapse
|